Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at email@example.com if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
The highly-anticipated fifth edition is here! Get the must-have resource for achieving compliance with medical device regulations.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
Posted 17 July 2012 | By Louise Zornoza,
The European Medicines Agency (EMA) has opened a consultation on the information changes to the summary of product characteristics (SmPC) and package leaflets mandated by the new European pharmacovigilance law.
The legislation requires the addition of information to the SmPC, which is aimed at healthcare professionals, and to the package leaflet, which is aimed at patients and consumers. This information is to include:
The proposed changes apply to all products whether approved through the centralized, mutual recognition or decentralized procedures. During the preparation for this public consultation, the EMA consulted European Union Member States, pharmaceutical industry associations and patient, consumer and healthcare-professional organizations on the new statements included in the draft revision of the template. The comment period closes on 17 August.
EMA - Quality Review of Documents (QRD) human product information annotated template: revision of the product information
More Breaking News from RegLink
Tags: SmPC, Consultation, pharmacovigilance